Impact of body mass index in patients with hepatocellular carcinoma treated with TACE combined with lenvatinib and PD-1 inhibitors

It is unclear how body mass index (BMI) affects individuals with hepatocellular carcinoma (HCC) receiving lenvatinib and programmed death receptor 1 (PD-1) inhibitors and transcatheter arterial chemoembolization (TACE). This study aims to evaluate the impact of BMI on the efficacy and safety of TACE...

Full description

Bibliographic Details
Published in:Oncologie
Main Authors: Wang Qishen, Liu Fang, Liu Chixiang, Lu Haoyu, Huang Zhen, Gong Xiaolong, Chen Quanwei, Li Na, Wu Chunxue, Zhang Hao, Han Jianjun
Format: Article
Language:English
Published: De Gruyter 2025-05-01
Subjects:
hepatocellular carcinoma (hcc)
lenvatinib
body mass index (bmi)
transcatheter arterial chemoembolization (tace)
diabetes
programmed death receptor 1 (pd-1) inhibitor
Online Access:https://doi.org/10.1515/oncologie-2025-0025
Description
Summary:It is unclear how body mass index (BMI) affects individuals with hepatocellular carcinoma (HCC) receiving lenvatinib and programmed death receptor 1 (PD-1) inhibitors and transcatheter arterial chemoembolization (TACE). This study aims to evaluate the impact of BMI on the efficacy and safety of TACE with systemic therapies in HCC patients.
ISSN:1765-2839

Similar Items